24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167 | Zendy

Hervé Hien | Zendy; N. Méda | Zendy; Serge Diagbouga | Zendy; Emmanuelle Zouré | Zendy; Souleymane Yaméogo | Zendy; Hassane Tamboura | Zendy; Jérôme W. Somé | Zendy; Adama Ouiminga | Zendy; François Rouet | Zendy; A Drabo | Zendy; A. Hien | Zendy; J Nicolas | Zendy; Hélène Chappuy | Zendy; Philippe Van de Perre | Zendy; Philippe Msellati | Zendy; Boubacar Nacro | Zendy

Open Access

24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167

Author(s) -

Hervé Hien,

N. Méda,

Serge Diagbouga,

Emmanuelle Zouré,

Souleymane Yaméogo,

Hassane Tamboura,

Jérôme W. Somé,

Adama Ouiminga,

François Rouet,

A Drabo,

A. Hien,

J Nicolas,

Hélène Chappuy,

Philippe Van de Perre,

Philippe Msellati,

Boubacar Nacro

Publication year - 2013

Publication title -

african health sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.391

H-Index - 44

eISSN - 1729-0503

pISSN - 1680-6905

DOI - 10.4314/ahs.v13i2.13

Subject(s) - efavirenz , didanosine , lamivudine , medicine , antiretroviral therapy , virology , human immunodeficiency virus (hiv) , nevirapine , viral load , virus , hepatitis b virus

There is no data on long-term benefit of once-a-day antiretroviral therapy (ART) with combination of DDI, 3TC and EFV to allow its use in future therapeutic strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research